查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589190

咳嗽過敏症候群治療藥物市場：按藥物類別、分銷管道分類 - 全球預測 2025-2030 年

Cough Hypersensitivity Syndrome Treatment Market by Drug Class (Anticholinergics, Antihistamines, Antitussive Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

咳嗽過敏症候群治療藥物市場2023年估值為92.1億美元，預計2024年將達到98.2億美元，複合年成長率為6.81%，到2030年將達到146.1億美元，預計將達到1000萬美元。

咳嗽過敏症候群（CHS）是一種複雜的臨床疾病，其特徵是對微不足道的刺激產生過度反應，導致慢性咳嗽。中樞性低通氣症候群治療解決方案的需求源自於對病患生活品質和醫療負擔的影響。應用主要集中在針對咳嗽反射途徑的先進藥物、行為療法和創新神經調節劑。最終用途廣泛，包括醫院、專科診所和研究機構。中樞性低通氣症候群 (CHS) 意識的提高、患者人數的增加以及診斷技術的進步推動了市場成長。人工智慧在診斷和個人化醫療中的整合提供了加深市場滲透的機會。因此，投資人工智慧主導的解決方案並與學術研究合作提供了一條創新之路。新興市場醫療保健支出不斷成長等經濟趨勢進一步支持了潛在的商機。然而，缺乏明確的生物標記和標準化治療方法使得早期準確診斷變得困難，市場面臨限制。此外，監管障礙和高昂的研發成本阻礙了新產品的開發。為了克服這些挑戰，公司應該專注於穩健的臨床試驗並與思想領袖合作。最有希望創新的領域包括非藥物干預措施的開發以及包括物理和心理技術在內的多學科治療方法的探索。此外，繼續研究了解中樞性低通氣症候群的病理學可能會發現新的治療標靶。這個市場本​​質上是多學科的，需要藥理學研究人員、臨床醫生和監管專家之間的合作。隨著對有效中樞性低通氣症候群治療方案的需求增加，市場相關人員必須利用前沿研究，同時透過策略規劃和創新來應對現有挑戰。透過使產品滿足未滿足的臨床需求並改善早期診斷工具，公司可以實現顯著成長並處於中樞性低通氣症候群治療市場的前沿。

主要市場統計
基準年[2023] 92.1億美元
預測年份 [2024] 98.2億美元
預測年份 [2030] 146.1億美元
複合年成長率（%） 6.81%

市場動態：快速發展的咳嗽過敏症候群治療市場的主要市場洞察

咳嗽過敏症候群藥物市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性肺部感染疾病高
    • 全球吸菸者人數迅速增加
    • 室內外過敏原的出現
  • 市場限制因素
    • 藥物濫用和對咳嗽過敏症候群藥物的依賴
  • 市場機會
    • 咳嗽過敏治療的研發迅速增加
    • 政府針對先進醫療基礎設施的舉措
  • 市場挑戰
    • 鎮咳藥物的療效有限且有不良副作用

波特的五力：駕馭咳嗽過敏症候群藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解咳嗽過敏症候群治療藥物市場的外部影響

外部宏觀環境因素在塑造咳嗽過敏症候群治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解咳嗽過敏症候群治療藥物市場的競爭狀況

對咳嗽過敏症候群治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣咳嗽過敏症候群治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估咳嗽過敏症候群治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製咳嗽過敏症候群治療藥物市場的成功之路

對咳嗽過敏症候群治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性肺部感染疾病高
      • 世界各地的吸煙者人數正在迅速增加
      • 脆弱的室內和室外過敏原的出現
    • 抑制因素
      • 藥物濫用和對咳嗽過敏藥物的依賴
    • 機會
      • 治療咳嗽過敏症候群的研發活動迅速增加
      • 政府致力於先進的醫療基礎設施
    • 任務
      • 鎮咳藥物的功效有限且有不良副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的咳嗽過敏症候群治療藥物市場

  • 抗膽鹼能藥物
  • 抗組織胺藥
  • 鎮咳藥
  • 吸入性皮質類固醇
  • 質子幫浦抑制劑
  • 短效BETA2激動劑

第7章咳嗽過敏症候群治療藥物市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章北美和南美咳嗽過敏症候群治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太咳嗽過敏症候群治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲咳嗽過敏症候群治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alvizia Healthcare Private Limited
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Farlex Pharmaceuticals Private Limited
  • GlaxoSmithKline PLC
  • Johnson & Johnson Consumer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Solace Biotech Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals, Inc.
  • WEEFSEL PHARMA
Product Code: MRR-4311CE1A33E2

The Cough Hypersensitivity Syndrome Treatment Market was valued at USD 9.21 billion in 2023, expected to reach USD 9.82 billion in 2024, and is projected to grow at a CAGR of 6.81%, to USD 14.61 billion by 2030.

Cough Hypersensitivity Syndrome (CHS) represents a complex clinical disorder characterized by an exaggerated response to trivial stimuli, leading to chronic cough. The necessity for CHS treatment solutions arises from its impact on patient quality of life and the healthcare burden it presents. Application primarily focuses on advanced pharmaceuticals, behavioral therapies, and innovative neuromodulators targeting the cough reflex pathway. End-use extends across hospitals, specialty clinics, and research institutes. Market growth is driven by increasing awareness of CHS, expanding patient populations, and advancements in diagnostic methodologies. The integration of artificial intelligence in diagnostics and personalized medicine offers opportunities for deeper market penetration. As such, investing in AI-driven solutions and collaboration with academic research provides a pathway to innovation. Economic trends like increased healthcare spending in emerging markets further boost potential opportunities. However, the market faces limitations due to the lack of definitive biomarkers and standardized treatments, making early and accurate diagnosis challenging. Furthermore, regulatory hurdles and high R&D costs can inhibit new product developments. To navigate these challenges, companies should focus on robust clinical trials and partnerships with key opinion leaders. The most promising areas for innovation include the development of non-pharmacological interventions and exploration of multidisciplinary treatment approaches involving both physical and psychological modalities. Furthermore, continued research into understanding the pathophysiology of CHS could unlock novel therapeutic targets. The market is inherently multidisciplinary, requiring collaboration between pharmacological researchers, clinicians, and regulatory experts. With the increasing demand for effective CHS treatment options, stakeholders in the market must leverage cutting-edge research while addressing existing challenges through strategic planning and innovation. By aligning product offerings with unmet clinical needs and improving early diagnostic tools, businesses can secure significant growth and position themselves at the forefront of the CHS treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 9.21 billion
Estimated Year [2024] USD 9.82 billion
Forecast Year [2030] USD 14.61 billion
CAGR (%) 6.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic lung infections diseases
    • Surge in the number of smokers globally
    • Emergence in vulnerable indoor as well as outdoor allergens
  • Market Restraints
    • Drug abuse and dependence on cough hypersensitivity syndrome drugs
  • Market Opportunities
    • Surge in research and development activities in the treatment of cough hypersensitivity syndrome
    • Government initiatives for advanced healthcare infrastructures
  • Market Challenges
    • Limited efficacy and undesirable side effects of antitussives

Porter's Five Forces: A Strategic Tool for Navigating the Cough Hypersensitivity Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cough Hypersensitivity Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cough Hypersensitivity Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cough Hypersensitivity Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cough Hypersensitivity Syndrome Treatment Market

A detailed market share analysis in the Cough Hypersensitivity Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cough Hypersensitivity Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cough Hypersensitivity Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cough Hypersensitivity Syndrome Treatment Market

A strategic analysis of the Cough Hypersensitivity Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cough Hypersensitivity Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Alvizia Healthcare Private Limited, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, Farlex Pharmaceuticals Private Limited, GlaxoSmithKline PLC, Johnson & Johnson Consumer Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Solace Biotech Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals, Inc., and WEEFSEL PHARMA.

Market Segmentation & Coverage

This research report categorizes the Cough Hypersensitivity Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anticholinergics, Antihistamines, Antitussive Agents, Inhales Corticosteroids, Proton Pump Inhibitors, and Short-Acting Beta-2 Agonists.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic lung infections diseases
      • 5.1.1.2. Surge in the number of smokers globally
      • 5.1.1.3. Emergence in vulnerable indoor as well as outdoor allergens
    • 5.1.2. Restraints
      • 5.1.2.1. Drug abuse and dependence on cough hypersensitivity syndrome drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in research and development activities in the treatment of cough hypersensitivity syndrome
      • 5.1.3.2. Government initiatives for advanced healthcare infrastructures
    • 5.1.4. Challenges
      • 5.1.4.1. Limited efficacy and undesirable side effects of antitussives
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cough Hypersensitivity Syndrome Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Antihistamines
  • 6.4. Antitussive Agents
  • 6.5. Inhales Corticosteroids
  • 6.6. Proton Pump Inhibitors
  • 6.7. Short-Acting Beta-2 Agonists

7. Cough Hypersensitivity Syndrome Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Cough Hypersensitivity Syndrome Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cough Hypersensitivity Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvizia Healthcare Private Limited
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. F. Hoffmann-La Roche AG
  • 6. Farlex Pharmaceuticals Private Limited
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Consumer Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer, Inc.
  • 12. Solace Biotech Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Vertex Pharmaceuticals, Inc.
  • 15. WEEFSEL PHARMA

LIST OF FIGURES

  • FIGURE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTITUSSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALES CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023